In collaboration with the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH) announced a third round of contract awards for scale-up and manufacturing of new COVID-19 testing technologies.
The six new Rapid Acceleration of Diagnostics (RADx) initiative contracts a total of $98.35 million for point-of-care and other novel testing approaches. They provide new modes of sample collection, processing, and return of results. Smart device integration, mobile-lab processing, and minute-ready test results are just some of the innovations to expect.
The NIH launched RADx to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing.
According to the RADx initiative webpage, it is "a national call for scientists and organizations to bring their innovative ideas for new COVID-19 testing approaches and strategies. Funded projects include new applications of existing technologies that make tests easier to use, easier to access, and more accurate."
“Since launching in April, the NIH RADx initiative has moved swiftly to facilitate critical expansion of early and late-stage testing technologies as well as research to remove barriers to testing for underserved and vulnerable populations,” said NIH Director Francis S. Collins, M.D., Ph.D in a recent press release. “Each of the technologies emerging from the RADx initiative will play a critical role in extending accessibility to testing in diverse settings.”
View the latest funding related to the RADx initiative here.
Surge of antidepressant use seen among female adolescents during COVID-19
March 7th 2024A study revealed a significant increase in antidepressant prescriptions among adolescents and young adults during the COVID-19 pandemic, particularly among female adolescents, indicating exacerbation of pre-existing mental health challenges.
Read More
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
COVID-19 vaccination during pregnancy not linked to preterm birth
January 31st 2024A systematic review of 6 studies revealed that COVID-19 vaccination during pregnancy does not significantly increase the risk of preterm birth, providing crucial insights for public health policies and offering reassurance to healthcare providers and expectant mothers.
Read More
Maternal COVID-19 vaccination deemed safe for infant neurodevelopment up to 18 months
January 23rd 2024A recent study found that in utero exposure to maternal COVID-19 vaccination poses no increased risk for neurodevelopmental impairment in infants up to 18 months of age, addressing concerns about the impact of vaccine exposure on unborn children.
Read More